• 1. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 2. Evidence of field induced slow magnetic relaxation in cis-[Co(hfac)2(H2O)2] exhibiting tri-axial anisotropy with a negative axial component?
  Denis V. Korchagin,Elena A. Yureva,Alexander V. Akimov,Eugenii Ya. Misochko,Gennady V. Shilov,Artem D. Talantsev,Roman B. Morgunov,Alexander A. Shakin,Sergey M. Aldoshin,Boris S. Tsukerblat Dalton Trans., 2017,46, 7540-7548
• 3. Fast-pulsing NMR techniques for the detection of weak interactions: successful natural abundance probe of hydrogen bonds in peptides?
  Amandine Altmayer-Henzien,Valérie Declerck,David J. Aitken,Ewen Lescop,Denis Merlet,Jonathan Farjon Org. Biomol. Chem., 2013,11, 7611-7615
• 4. Embedding cyclic nitrone in mesoporous silica particles for EPR spin trapping of superoxide and other radicals?
  Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
• 5. Evidence of CO2 molecule acting as an electron acceptor on a nanoporous metal–organic-framework MIL-53 or Cr3+(OH)(O2C–C6H4–CO2)?
  Alexandre Vimont,Arnaud Travert,Philippe Bazin,Jean-Claude Lavalley,Marco Daturi,Christian Serre,Gérard Férey,Sandrine Bourrelly,Philip L. Llewellyn Chem. Commun., 2007, 3291-3293

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Heteroaromatic compounds Heteroaromatic compounds
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Heteroaromatic compounds

Recent Advances in the Study of 2-(Ethoxymethyl)furan (CAS: 6270-56-0) in Chemical Biology and Pharmaceutical Research

The compound 2-(Ethoxymethyl)furan (CAS: 6270-56-0) has recently garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential applications in drug development. This heterocyclic organic compound, characterized by a furan ring substituted with an ethoxymethyl group, exhibits promising biological activities, including antimicrobial, antifungal, and anti-inflammatory properties. Recent studies have explored its synthesis, mechanism of action, and therapeutic potential, positioning it as a candidate for further investigation in medicinal chemistry.

One of the key areas of research focuses on the synthetic pathways for 2-(Ethoxymethyl)furan. A study published in the Journal of Organic Chemistry (2023) detailed an efficient, one-pot synthesis method using furfural as a starting material, followed by etherification with ethanol in the presence of a Lewis acid catalyst. This method achieved a high yield (85%) and excellent purity, making it suitable for large-scale production. The study also highlighted the compound's stability under various pH conditions, which is crucial for its potential use in pharmaceutical formulations.

In terms of biological activity, recent in vitro studies have demonstrated that 2-(Ethoxymethyl)furan exhibits potent inhibitory effects against a range of Gram-positive bacteria, including Staphylococcus aureus and Streptococcus pneumoniae. A 2024 study in the European Journal of Medicinal Chemistry reported that the compound disrupts bacterial cell membrane integrity, leading to cell lysis. Additionally, it showed synergistic effects when combined with conventional antibiotics, suggesting its potential as an adjuvant therapy for resistant bacterial infections.

Another promising avenue of research involves the anti-inflammatory properties of 2-(Ethoxymethyl)furan. A preclinical study published in Bioorganic & Medicinal Chemistry Letters (2023) investigated its effects on lipopolysaccharide (LPS)-induced inflammation in murine macrophages. The results indicated that the compound significantly reduced the production of pro-inflammatory cytokines, such as TNF-α and IL-6, by inhibiting the NF-κB signaling pathway. These findings suggest its potential application in treating chronic inflammatory diseases, such as rheumatoid arthritis and inflammatory bowel disease.

Despite these advancements, challenges remain in the development of 2-(Ethoxymethyl)furan as a therapeutic agent. Pharmacokinetic studies have revealed limited oral bioavailability, prompting researchers to explore prodrug strategies or novel delivery systems, such as nanoparticles, to enhance its absorption and distribution. Furthermore, toxicological assessments are ongoing to ensure its safety profile meets regulatory standards for clinical use.

In conclusion, 2-(Ethoxymethyl)furan (CAS: 6270-56-0) represents a versatile compound with significant potential in chemical biology and pharmaceutical applications. Ongoing research aims to optimize its synthesis, elucidate its mechanisms of action, and overcome pharmacokinetic limitations. As the scientific community continues to uncover its therapeutic benefits, this compound may soon transition from the laboratory to clinical trials, offering new treatment options for infectious and inflammatory diseases.

• 139112-81-5(Furan, 2,5-bis(propoxymethyl)-)
• 13679-46-4(Furan,2-(methoxymethyl)-)
• 61852-25-3(2,5,8,11-Tetraoxatridecan-13-ol, 1,1'-(2,5-furandiyl)bis-)
• 4437-22-3(2,2'-(Oxybis(methylene))difuran)
• 113983-97-4(5-(ethoxymethyl)-2-Furanmethanol)
• 13678-72-3(Furan, 2-[(2-furanylmethoxy)methyl]-5-methyl-)
• 113505-00-3(Furan, 2-[(2-propenyloxy)methyl]-)
• 31692-86-1(Poly(oxy-1,2-ethanediyl),a-(2-furanylmethyl)-w-hydroxy-)
• 934-93-0(5-(methoxymethyl)furan-2-ylmethanol)
• 110339-33-8(2-[(2-methylpropan-2-yl)oxymethyl]furan)